Search Results for: Ca

Press 20/20 GeneSystems Enters Engagement Agreement with ClearingBid, Pioneer of the First “Crowd-Powered” Open IPOs 20/20 GeneSystems, Inc., an early market leader in multi-cancer early detection blood testing, announces that it has entered an Engagement Agreement with ClearingBid, Inc., a provider of the first platform enabling ordinary individuals and institutions to invest in IPOs at

Meet our Team Executive Management Jonathan Cohen President & CEO Mr. Cohen is the founder of our company and has served as Chief Executive Officer, President, and a director since its inception. He is a co-inventor of two of our most successful products, OneTest and BioCheck, and has led the commercial launch and sales of

20/20 GeneSystems We Modernize Clinical Lab Testing with Machine Learning and Real-World Data Learn More Our Products OneTest™ for Cancer OneTest is the first test of its kind to combine the results of six cancer biomarker tests (from a single blood draw) and personal health data with an artificial intelligence algorithm to calculate a probability

Investor Relations About 20/20 GeneSystems 20/20 GeneSystems, Inc. is a U.S. based privately held corporation based in Maryland.  Investment in the company is currently open for Angel, Private and Institutional investors.  Investors are invited to review our current Wefunder investment campaign by clicking the link below.  Go to Wefunder Campaign 20/20 GeneSystems is offering investments

Our Team Jonathan Cohen Founder, CEO Jonathan Cohen is the founder, president, and CEO of 20/20 GeneSystems. Under Mr. Cohen’s leadership, 20/20 has brought in approximately $7.5 million in grant funding and launched two successful products, a bio-detection kit for suspicious powders used by hundreds of emergency responder organizations worldwide and a blood test for

Investing with 20/20 Investors Welcome! 20/20 GeneSystems is a U.S. based private corporation located in Maryland.  Investment opportunities are currently available and as a Reg A+ company, anyone can become a shareholder in our company. We have raised more than $5 million in equity crowd funding, making us one of the most successful crowd-funding life

The Future of Cancer Screening 20/20 GeneSystems pioneers innovative bio-testing and cancer diagnostic tools that address compelling unmet needs. 20/20’s digital diagnostics business develops and commercializes A.I. powered cancer screenings tests deliver better tools to improve early detection of the most common cancers globally. Our emergency bio-detection business includes our patented BioCheck which is widely used by emergency responders.